News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Visterra, Inc. Adds $8 Million, Ex-AMAG Pharmaceuticals, Inc. (AMAG) Execs, To Begin Clinical Push For Flu Antibody


12/2/2013 8:49:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Visterra has spent four years designing and fine-tuning an antibody that it thinks can combat all types of influenza. Now it’s pocketed some cash and filled out a revamped management team to take that drug into the clinic.

Cambridge, MA-based Visterra has added $8.1 million in venture dollars to its bank account, representing the third and final tranche from a $34.2 million Series A round that the company began raising last year.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy
Read at News-Medical
Read at Boston Business Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES